Junwei Shi
Cited by
Cited by
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ...
Cell 146 (6), 904-917, 2011
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
J Zuber, J Shi, E Wang, AR Rappaport, H Herrmann, EA Sison, D Magoon, ...
Nature 478 (7370), 524-528, 2011
Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control
I Barbieri, K Tzelepis, L Pandolfini, J Shi, G Millán-Zambrano, SC Robson, ...
Nature 552 (7683), 126-131, 2017
The mechanisms behind the therapeutic activity of BET bromodomain inhibition
J Shi, CR Vakoc
Molecular cell 54 (5), 728-736, 2014
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
J Shi, E Wang, JP Milazzo, Z Wang, JB Kinney, CR Vakoc
Nature biotechnology 33 (6), 661-667, 2015
Roles of Arabidopsis WRKY18, WRKY40 and WRKY60 transcription factors in plant responses to abscisic acid and abiotic stress
H Chen, Z Lai, J Shi, Y Xiao, Z Chen, X Xu
BMC plant biology 10 (1), 1-15, 2010
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
J Shi, WA Whyte, CJ Zepeda-Mendoza, JP Milazzo, C Shen, JS Roe, ...
Genes & development 27 (24), 2648-2662, 2013
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability
B King, T Trimarchi, L Reavie, L Xu, J Mullenders, P Ntziachristos, ...
Cell 153 (7), 1552-1566, 2013
Optimized base editors enable efficient editing in cells, organoids and mice
MP Zafra, EM Schatoff, A Katti, M Foronda, M Breinig, AY Schweitzer, ...
Nature biotechnology 36 (9), 888-893, 2018
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance
J Zuber, AR Rappaport, W Luo, E Wang, C Chen, AV Vaseva, J Shi, ...
Genes & development 25 (15), 1628-1640, 2011
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
YH Huang, O Klingbeil, XY He, XS Wu, G Arun, B Lu, TDD Somerville, ...
Genes & development 32 (13-14), 915-928, 2018
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia (AML)
H Herrmann, K Blatt, J Shi, KV Gleixner, S Cerny-Reiterer, L Müllauer, ...
Oncotarget 3 (12), 1588, 2012
BET bromodomain inhibition releases the mediator complex from select cis-regulatory elements
AS Bhagwat, JS Roe, BYL Mok, AF Hohmann, J Shi, CR Vakoc
Cell reports 15 (3), 519-530, 2016
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
AF Hohmann, LJ Martin, JL Minder, JS Roe, J Shi, S Steurer, G Bader, ...
Nature chemical biology 12 (9), 672-679, 2016
NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler
C Shen, JJ Ipsaro, J Shi, JP Milazzo, E Wang, JS Roe, Y Suzuki, ...
Molecular cell 60 (6), 847-859, 2015
Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia
E Wang, S Kawaoka, M Yu, J Shi, T Ni, W Yang, J Zhu, RG Roeder, ...
Proceedings of the National Academy of Sciences 110 (10), 3901-3906, 2013
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
GL Brien, D Remillard, J Shi, ML Hemming, J Chabon, K Wynne, ...
Elife 7, e41305, 2018
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
JD Grevet, X Lan, N Hamagami, CR Edwards, L Sankaranarayanan, X Ji, ...
Science 361 (6399), 285-290, 2018
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
CC Bell, KA Fennell, YC Chan, F Rambow, MM Yeung, D Vassiliadis, ...
Nature communications 10 (1), 2723, 2019
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9; NrasG12D acute myeloid leukemia
J Shi, E Wang, J Zuber, A Rappaport, M Taylor, C Johns, SW Lowe, ...
Oncogene 32 (7), 930-938, 2013
The system can't perform the operation now. Try again later.
Articles 1–20